ライフサイエンスコーパス: matrix metalloproteinase 9

1 n in syndecan-1, increase in heparanase, and matrix metalloproteinase 9).

2 C-terminal region, via the action of MMP-9 (matrix metalloproteinase 9).

3 ing expression of macrophage-specific MMP-9 (matrix metalloproteinase-9).

4 asion (intercellular adhesion molecule-1 and matrix metalloproteinase-9).

5 flammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9).

6 trix metalloproteinase-12) and gelatinase B (matrix metalloproteinase-9).

7 obial peptides (RegIIIbeta, RegIIIgamma) and matrix metalloproteinase 9.

8 ture NGF (mNGF) and that mNGF is degraded by matrix metalloproteinase 9.

9 h factor, platelet-derived growth factor, or matrix metalloproteinase 9.

10 t testis, likely via proteolytic cleavage of matrix metalloproteinase 9.

11 vated receptor gamma, and reducing Snail and matrix metalloproteinase 9.

12 stress fibers, and reduce the expression of matrix metalloproteinase 9.

13 press CHIT activity and enhance secretion of matrix metalloproteinase 9.

14 ed to reduction of their levels of CD62L and matrix metalloproteinase-9.

15 This increase was independent of matrix metalloproteinase-9.

16 ation of myeloid cells expressing S100A8 and matrix metalloproteinase-9.

17 progression possibly in part by stabilizing matrix metalloproteinase-9.

18 of the NF-kappaB target genes IL-8, IL-6 and matrix metalloproteinase-9.

19 tic, express macrophage markers, and secrete matrix metalloproteinase-9.

20 nism involving the PI3K/AKT/mTOR pathway and matrix metalloproteinase-9.

21 n in stem cells in vivo and in vitro through matrix metalloproteinase-9.

22 minin, and insoluble elastin, as potently as matrix metalloproteinase-9.

23 0), kallikrein (0.73), lipoprotein a (1.29), matrix metalloproteinase 9 (1.30), the interaction term

24 .9 vs 3753.2 +/- 1106.0 pg/mL, P = .03), and matrix metalloproteinase-9 (101 515.6 +/- 37 088.4 vs 14

25 d), tissue plasminogen activator (2.7-fold), matrix metalloproteinase-9 (4.1-fold), and Factor Xa (3.

26 lycosaminoglycans, lysosomal hydrolases, and matrix metalloproteinase 9, a known modulator of Lyme ar

27 amphiregulin, a growth factor that regulates matrix metalloproteinase-9; a shift in transforming grow

28 as myeloperoxidase, neutrophil elastase, and matrix metalloproteinase 9, activates macrophages throug

29 n degradation by inhibiting plasmin-mediated matrix metalloproteinase 9 activation.

30 nhibits plasminogen activation and regulates matrix metalloproteinase-9 activation and macrophage rec

31 mmatory models, and was sufficient to reduce matrix metalloproteinase-9 activation and macrophage rec

32 treatment reduced intravasation by reducing matrix metalloproteinase-9 activities.

33 han ROS neutralization resulted in decreased matrix metalloproteinase 9 activity as well as loss of m

34 r-1, and an associated threefold increase in matrix metalloproteinase 9 activity compared with LCWE a

35 ereas the latter was associated with reduced matrix metalloproteinase 9 activity.

36 In addition, PKal inhibition reduced matrix metalloproteinase-9 activity in brain following s

37 Importantly, neutralization of matrix metalloproteinase-9 activity in Ceacam1(-/-) mice

38 tumor formation and metastasis with reduced matrix metalloproteinase-9 activity in the blood.

39 For murine macrophages, matrix metalloproteinase-9 activity was found to be requ

40 -induced migratory responsiveness, decreased matrix metalloproteinase-9 activity, and increased neuro

41 ACS-1 also inhibited matrix metalloproteinase-9 activity, cellular migration,

42 Matrix metalloproteinase 9 and 13 expression and matrix

43 Lung matrix metalloproteinase 9 and 2 activities increased, w

44 ed that PKC similarly regulated secretion of matrix metalloproteinase 9 and chitinase-3-like-1 protei

45 increased levels and activity of circulating matrix metalloproteinase 9 and elevated angiostatin leve

46 elastase) and selected inflammatory markers (matrix metalloproteinase 9 and interleukin [IL]-17).

47 It is a major inducer of matrix metalloproteinase 9 and is selectively toxic for

48 lease of the granules' contents, measured as matrix metalloproteinase 9 and neutrophil elastase activ

49 (a precursor of peroxide that activates pro-matrix metalloproteinase 9 and osteogenic signaling in v

50 ling of epidermal growth factor receptor and matrix metalloproteinase 9 and resulted in suppression o

51 Additionally, levels of matrix metalloproteinase 9 and the chemokines C-C motif

52 activin A and GM-CSF; and metalloproteinases matrix metalloproteinase-9 and a disintegrin and metallo

53 ls with CLS in SAT exhibited upregulation of matrix metalloproteinase-9 and monocyte antigen CD14 gen

54 peptides and Bhsp65, and of the activity of matrix metalloproteinase-9 and phospho-ERK.

55 nt, including increases in the following: i) matrix metalloproteinase-9 and proinflammatory mediator

56 hase (eNOS) and 2 targets of eNOS signaling, matrix metalloproteinase-9 and soluble Kit ligand.

57 lueberry treatment decreased the activity of matrix metalloproteinase-9 and the secretion of urokinas

58 T cells display helper function for monocyte matrix metalloproteinase-9 and tissue factor production

59 on of beta2GPI-specific T cells for monocyte matrix metalloproteinase-9 and tissue factor production,

60 mDCs; moreover, mDCs secreted high levels of matrix metalloproteinase-9 and upregulated C1q, heat sho

61 ction of other tumorigenic factors including matrix metalloproteinase-9 and vascular endothelial grow

62 CD163(+) TAMs produced protumoral factors, matrix metalloproteinases 9 and 11 (MMP9 and MMP11), at

63 ability and bioactivity via the secretion of matrix metalloproteinases 9 and heparanase.

64 a secreted glycoprotein that binds to MMP-9 (matrix metalloproteinase 9) and protects it from degrada

65 cFLIP), proliferation (cyclin D1), invasion (matrix metalloproteinase-9), and angiogenesis (vascular

66 ess Sema3a induces dysregulation of nephrin, matrix metalloproteinase 9, and alphavbeta3 integrin in

67 O synthase (iNOS)), cell adhesion molecules, matrix metalloproteinase 9, and chemokine (RANTES).

68 As involved in these processes (e.g., Actin, matrix metalloproteinase 9, and cyclin D1 and B1).

69 levated mRNA and protein levels of IL-12p40, matrix metalloproteinase 9, and inducible NO synthase, w

70 molecule 1 [ICAM-1], myeloperoxidase [MPO], matrix metalloproteinase 9, and vascular cell adhesion m

71 n matrix-degrading proteases cathepsin S and matrix metalloproteinase-9, and systemic serum amyloid A

72 hway and by upregulating expression of CD44, matrix metalloproteinase-9, and the hyaluronan-mediated

73 protein-47 (markers of collagen synthesis), matrix metalloproteinase-9, and tissue inhibitor metallo

74 at the levels of matrix metalloproteinase-2, matrix metalloproteinase-9, and transforming growth fact

75 al ECs produced up to 61% less NO, IL-8, and matrix metalloproteinase-9, and up to 3-fold more activi

76 genase-2, intercellular adhesion molecule-1, matrix metalloproteinase-9, and vascular endothelial gro

77 ic factors in tumors, including IL-1beta and matrix metalloproteinase-9, and we found upregulation of

78 or bearing as well as expression of IL-8 and matrix metalloproteinase 9, ankle loading decreased them

79 ncode vascular endothelial growth factor and matrix metalloproteinase-9 are stabilized when murine ma

80 groups of EC and NS (myeloperoxidase [MPO], matrix metalloproteinase-9) as well as between DS and EC

81 Up-regulation of matrix metalloproteinase-9 associated with astrocyte act

82 s of IgE and neutrophil-generated mediators, matrix metalloproteinase-9, B-cell activating factor, tr

83 ta1 promoted the expression and secretion of matrix metalloproteinase-9 by podocytes.

84 expression of the osteoclast genes encoding matrix metalloproteinase 9, cathepsin K, tartrate-resist

85 f inflammatory genes including CD68, leptin, matrix metalloproteinase-9, CD163, and CD8A were signifi

86 ues from symptomatic patients that comprised matrix metalloproteinase 9, chitinase 3-like-1, S100 cal

87 1.048 g/mL released higher levels of active matrix metalloproteinase 9 compared with cells from nons

88 atients also produced elevated quantities of matrix metalloproteinase 9, consistent with a capacity t

89 in-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reducti

90 s desmin, fibroblast-specific protein-1, and matrix metalloproteinase-9 could be observed in glomerul

91 migration inhibitory factor (MIF), VEGF, and matrix metalloproteinase 9, creating a microenvironment

92 Various concentrations of matrix-metalloproteinase-9-digested Col-I fibers on NCsf

93 gh levels of matrix metalloproteinase-14 and matrix metalloproteinase-9 expressed by the wrapping ECs

94 tracellular matrix remodeling is mediated by matrix metalloproteinase-9 expressed in macrophages with

95 Increased invasion was mediated by matrix metalloproteinase 9 expression and activity in th

96 ltration, glutathione-synthesizing capacity, matrix metalloproteinase 9 expression and neointimal smo

97 This was associated with decreased matrix metalloproteinase 9 expression and reduced loss o

98 Neointimal SMC proliferation and medial SMC matrix metalloproteinase 9 expression were not altered b

99 VIP gene haploinsufficiency results in lower matrix metalloproteinase 9 expression, and reduced migra

100 rtas had decreased inflammatory cytokine and matrix metalloproteinase 9 expression.

101 Matrix metalloproteinase-9 expression was increased in B

102 vasion and migration associated with reduced matrix metalloproteinase-9 expression.

103 regulatory factor 3, which directly induced matrix metalloproteinase-9 expression.

104 diated targeting activated AKT and increased matrix metalloproteinase-9 expression.

105 for C-reactive protein; prostaglandin E(2); matrix metalloproteinase-9; fibrinogen; endotoxin; inter

106 extend this work to show that in addition to matrix metalloproteinase 9, hypoxia-inducible factor 1al

107 nt decrease in the amount of neutrophils and matrix metalloproteinase 9 in the tissues, and the mitig

108 e comparable in modulating the expression of matrix metalloproteinase-9 in bronchoalveolar lavage.

109 assay and alphavbeta6 mediated production of matrix metalloproteinase-9 in Calu-3 cells.

110 roduction, and release of neutrophil-related matrix metalloproteinase-9 in Ceacam1(-/-) mice were con

111 rkers of neurovascular remodeling, including matrix metalloproteinase-9 in GFAP-positive astrocytes a

112 IL-8 in turn controls the production of matrix metalloproteinase-9 in keratinocytes.

113 ted increases in the expression of Rho-A and matrix metalloproteinase-9 in LRs, and (3) Tat-mediated

114 This chemokine activated matrix metalloproteinase-9 in neutrophils, allowing thei

115 ed neutrophil oxidative burst and release of matrix metalloproteinase-9 in vitro.

116 a-2-macroglobulin or the hemopexin domain of matrix metalloproteinase 9) induces TrkC, Akt, and ERK a

117 uclear factor-kappaB activity, inhibition of matrix metalloproteinase-9 induction, the maintenance of

118 beyond drug clearance.SIGNIFICANCE STATEMENT Matrix metalloproteinase-9 inhibition appears to attenua

119 artery bypass graft-induced increased plasma matrix metalloproteinase-9, interleukin-6, and C-reactiv

120 Matrix metalloproteinase 9 is an inflammatory biomarker

121 Matrix metalloproteinase-9 is implicated in airway infla

122 The ability to accurately detect elevated matrix metalloproteinase 9 levels may lead to earlier di

123 Reducing the matrix metalloproteinase-9 levels by RNA interference in

124 In vitro, IL-20 upregulated matrix metalloproteinase-9, matrix metalloproteinase-12,

125 Matrix metalloproteinase 9, metalloproteinase inhibitor

126 Macrophages expressing matrix metalloproteinase-9 migrate to the deteriorating

127 ignificant increase in collagen degradation, matrix metalloproteinase 9 (MMP-9) activity and tissue d

128 action as well as tear collection to measure matrix metalloproteinase 9 (MMP-9) activity were perform

129 is was associated with decreased circulating matrix metalloproteinase 9 (MMP-9) and increased circula

130 ukin (IL) -12, IL-1 receptor antagonist, and matrix metalloproteinase 9 (MMP-9) and increased macroph

131 n revealed that it induces the expression of matrix metalloproteinase 9 (MMP-9) and MMP-13, both of w

132 Matrix metalloproteinase 9 (MMP-9) antisense oligonucleo

133 Retinoic acid (RA) inhibits matrix metalloproteinase 9 (MMP-9) expression due to AP-

134 We reported previously that PGE2 induces matrix metalloproteinase 9 (MMP-9) expression in DCs and

135 4 antagonist, AMD also up-regulated VEGF and matrix metalloproteinase 9 (MMP-9) expression, and the b

136 in vivo, primarily through the inhibition of matrix metalloproteinase 9 (MMP-9) expression.

137 r the quantitation of the zinc endopeptidase matrix metalloproteinase 9 (MMP-9) from mouse serum.

138 We recently demonstrated that matrix metalloproteinase 9 (MMP-9) induces significant a

139 Matrix metalloproteinase 9 (MMP-9) is a critical mediato

140 Matrix Metalloproteinase 9 (MMP-9) is an enzyme involved

141 Matrix metalloproteinase 9 (MMP-9) is present in arteria

142 Activation of matrix metalloproteinase 9 (MMP-9) paralleled injury, bu

143 The expression of matrix metalloproteinase 9 (MMP-9) was suppressed when T

144 ar junctions concurrently with expression of matrix metalloproteinase 9 (MMP-9), a marker of fast MNs

145 Cathepsin B increased the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved i

146 kin-8 (IL-8), epidermal growth factor (EGF), matrix metalloproteinase 9 (MMP-9), and interleukin-1 be

147 at B. burgdorferi induces the host protease, matrix metalloproteinase 9 (MMP-9), and suggested that t

148 ed increased p308 and significant amounts of matrix metalloproteinase 9 (MMP-9), and these effects we

149 splayed a high level of enzymatically active matrix metalloproteinase 9 (MMP-9), and were capable of

150 autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 rel

151 n of adherens junctions through induction of matrix metalloproteinase 9 (MMP-9).

152 llagen I were reduced as was the activity of matrix metalloproteinase 9 (MMP-9).

153 cipal H3NT protease of osteoclastogenesis is matrix metalloproteinase 9 (MMP-9).

154 The involvement of matrix metalloproteinase-9 (MMP-9) activities in the dev

155 ed by increased proliferation, invasion, and matrix metalloproteinase-9 (MMP-9) activity (approximate

156 Uncontrolled increases of matrix metalloproteinase-9 (MMP-9) activity have been ca

157 Measurement of matrix metalloproteinase-9 (MMP-9) activity in the media

158 There is a well-documented association of matrix metalloproteinase-9 (MMP-9) and receptor Notch-1

159 showed significantly elevated expression of matrix metalloproteinase-9 (MMP-9) and reduced expressio

160 ion-on-chip (ChIP-on-chip) assay, identified matrix metalloproteinase-9 (MMP-9) as a direct target of

161 he objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomark

162 tissue-type plasminogen activator (tPA) and matrix metalloproteinase-9 (MMP-9) can produce BBB damag

163 We previously demonstrated that matrix metalloproteinase-9 (MMP-9) contributes to the pa

164 We characterized a high matrix metalloproteinase-9 (MMP-9) expressing U1242 MG i

165 Matrix metalloproteinase-9 (MMP-9) expression is known t

166 IL-1beta has been reported to induce matrix metalloproteinase-9 (MMP-9) expression.

167 riptional activation of the matrix-degrading matrix metalloproteinase-9 (MMP-9) gene, a crucial media

168 The dysregulation of matrix metalloproteinase-9 (MMP-9) has been implicated i

169 An excessive amount of matrix metalloproteinase-9 (MMP-9) has been well documen

170 e have investigated the possible function of matrix metalloproteinase-9 (MMP-9) in alcohol addiction

171 addition to downregulating the expression of matrix metalloproteinase-9 (MMP-9) in hepatic IRI, CS-1

172 sma and ELISA demonstrates reduced levels of matrix metalloproteinase-9 (MMP-9) in the plasma and bra

173 Diabetes activates matrix metalloproteinase-9 (MMP-9) in the retina and its

174 We report that matrix metalloproteinase-9 (MMP-9) in the spinal cord co

175 Matrix metalloproteinase-9 (MMP-9) is a potent regulator

176 Matrix metalloproteinase-9 (MMP-9) is active in islets a

177 Matrix metalloproteinase-9 (MMP-9) is an extracellular p

178 Matrix metalloproteinase-9 (MMP-9) is important in numer

179 Activation of matrix metalloproteinase-9 (MMP-9) is involved in HIV-1-

180 Here we provide conclusive evidence that matrix metalloproteinase-9 (MMP-9) is necessary to the d

181 Matrix metalloproteinase-9 (MMP-9) is required for struc

182 , leading to abdominal aortic aneurysms, and matrix metalloproteinase-9 (MMP-9) is the predominant en

183 Liver matrix metalloproteinase-9 (MMP-9) mRNA and MMP-2 mRNA w

184 ellular matrix-degrading enzyme gelatinase B/matrix metalloproteinase-9 (Mmp-9) on islet function in

185 Matrix metalloproteinase-9 (MMP-9) plays a critical role

186 Matrix metalloproteinase-9 (MMP-9) plays an important ro

187 Matrix metalloproteinase-9 (MMP-9) produced by colorecta

188 F) attenuate macrophage Tie-2 expression and matrix metalloproteinase-9 (MMP-9) production.

189 The aim of this study was to combine matrix metalloproteinase-9 (MMP-9) protein (enzyme-linke

190 the mechanisms by which increased levels of matrix metalloproteinase-9 (MMP-9) protein causes myopat

191 Matrix metalloproteinase-9 (MMP-9) represents one of the

192 ate that Brucella abortus infection inhibits matrix metalloproteinase-9 (MMP-9) secretion and induces

193 ranscription factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these ce

194 ta1), collagen deposition, and inhibition of matrix metalloproteinase-9 (MMP-9) secretion.

195 Matrix metalloproteinase-9 (MMP-9) synthesis is detected

196 Moreover, matrix metalloproteinase-9 (MMP-9) synthesis, which faci

197 osphatase staining, whereas the secretion of matrix metalloproteinase-9 (MMP-9) was measured by ELISA

198 tumor necrosis factor-alpha (TNF-alpha) and matrix metalloproteinase-9 (MMP-9) was performed on the

199 ith previous in vitro findings, the level of matrix metalloproteinase-9 (MMP-9) was reduced in MCP-1-

200 ontribute to neovascularization by supplying matrix metalloproteinase-9 (MMP-9), a protease that has

201 Matrix metalloproteinase-9 (MMP-9), a proteolytic enzyme

202 An mCherry fusion protein of matrix metalloproteinase-9 (MMP-9), a secreted glycoprot

203 We next determined whether matrix metalloproteinase-9 (MMP-9), an angiogenic factor

204 Recent studies indicate that matrix metalloproteinase-9 (MMP-9), an endopeptidase tha

205 tic receptor for diverse proteins, including matrix metalloproteinase-9 (MMP-9), and a cell-signaling

206 superoxide dismutase (SOD), catalase (CAT), matrix metalloproteinase-9 (MMP-9), and cardiac Troponin

207 Diabetes activates retinal matrix metalloproteinase-9 (MMP-9), and MMP-9 damages th

208 f an enzyme that is downstream of caspase-1, matrix metalloproteinase-9 (MMP-9), and protein levels o

209 LDD therapies in reducing gingival levels of matrix metalloproteinase-9 (MMP-9), interleukin-1beta (I

210 cell characteristics including secretion of matrix metalloproteinase-9 (MMP-9), invasion, and colony

211 One of these, matrix metalloproteinase-9 (MMP-9), is expressed only by

212 tion and reduced expression of Ki-67, COX-2, matrix metalloproteinase-9 (MMP-9), NF-kappaB p65, and V

213 molecules (VCAM-1 and ICAM-1, respectively), matrix metalloproteinase-9 (MMP-9), tumor necrosis facto

214 eneration of the tissue remodelling protease matrix metalloproteinase-9 (MMP-9).

215 TIMP-1) is the major endogenous regulator of matrix metalloproteinase-9 (MMP-9).

216 containing the cleavage site for the enzyme matrix metalloproteinase-9 (MMP-9).

217 acological inhibition or genetic ablation of matrix metalloproteinase-9 (MMP-9).

218 We report that matrix metalloproteinase-9 (MMP-9, extracellularly opera

219 tor-1 (SDF-1)/CXCL12 in the injured cord and matrix metalloproteinase-9 (MMP-9/gelatinase B), express

220 ially by modulating the activity of secreted matrix metalloproteinases 9 (MMP-9).

221 nd label-free detection of recombinant human matrix metalloproteinases-9 (MMP-9), which has been asso

222 h a reduction in synthesis and activation of matrix metalloproteinase 9 (MMP9) and altered fibronecti

223 increased chondrocytic expression of Rankl, matrix metalloproteinase 9 (Mmp9) and Mmp13 and enhanced

224 n addition, they produce large quantities of matrix metalloproteinase 9 (MMP9) and promote vascular r

225 proinflammatory cytokine TNFalpha stimulates matrix metalloproteinase 9 (MMP9) at the ocular surface

226 Matrix metalloproteinase 9 (MMP9) contributes to this pr

227 this oxidized and activated CaMKII promotes matrix metalloproteinase 9 (MMP9) expression in cardiomy

228 sed ventricular superoxide levels, increased matrix metalloproteinase 9 (Mmp9) expression, and reduce

229 (fgf8a) expression and positively regulates matrix metalloproteinase 9 (mmp9) expression.

230 Although matrix metalloproteinase 9 (Mmp9) has been implicated in

231 histoenzymology, and cathepsin B (CATB) and matrix metalloproteinase 9 (MMP9) immunochemistry.

232 ated the expression of the metalloproteinase matrix metalloproteinase 9 (MMP9) in human breast cancer

233 hase 2 (Nos2), interleukin 1beta (Il1b), and matrix metalloproteinase 9 (Mmp9) in the gingiva; suppor

234 o a 7.0 +/- 1.6 (P < 0.05)-fold induction of matrix metalloproteinase 9 (MMP9) in the host lung.

235 Matrix metalloproteinase 9 (MMP9) is a member of a large

236 Matrix metalloproteinase 9 (MMP9) is expressed in teeth

237 Here we show that matrix metalloproteinase 9 (MMP9) is involved in WNV ent

238 Matrix metalloproteinase 9 (MMP9) mRNA, which encodes a

239 hen recruits p38gamma as a cofactor into the matrix metalloproteinase 9 (MMP9) promoter to induce its

240 Further, mutation of matrix metalloproteinase 9 (mmp9) results in delayed gro

241 ced microglia activation and redox-sensitive matrix metalloproteinase 9 (MMP9) stimulation, leading t

242 The relative expression of galectin-3 and matrix metalloproteinase 9 (MMP9) was evaluated by quant

243 Only matrix metalloproteinase 9 (MMP9) was validated; in pre-

244 n that chronic wounds exhibit high levels of matrix metalloproteinase 9 (MMP9), a key proteolytic enz

245 ignal-regulated kinase-1/2 (ERK1/2), AKT and matrix metalloproteinase 9 (MMP9), and inhibited the mot

246 nterleukin-1beta (IL-1beta), IL-6, CCL5, and matrix metalloproteinase 9 (MMP9), in addition to induct

247 Matrix metalloproteinase 9 (MMP9), which degrades NGF, w

248 zes combretastatin A4 nanodrug (CA4-NPs) and matrix metalloproteinase 9 (MMP9)-activated doxorubicin

249 activity and differentiation, in particular matrix metalloproteinase 9 (MMP9).

250 Here, we show that levels of the matrix metalloproteinase-9 (MMP9) decrease, and the leve

251 Here we show that matrix metalloproteinase-9 (MMP9) deficiency causes phys

252 polarization, and (iv) TNF-alpha-stimulated matrix metalloproteinase-9 (MMP9) expression and activit

253 s long been implicated in virulence, induced matrix metalloproteinase-9 (MMP9) in epithelial cells ne

254 Inappropriate elevation of matrix metalloproteinase-9 (MMP9) is reported to be invo

255 Remarkably, proteinases including matrix metalloproteinase-9 (Mmp9) released from endothel

256 ulation of tumor-secreted factors, including matrix metalloproteinase-9 (MMP9), fibronectin (FN), and

257 ic inflammation and endothelial dysfunction (matrix metalloproteinase-9, myeloperoxidase, plasminogen

258 We observed upregulation of matrix metalloproteinase 9, N-cadherin, and fibronectin

259 ongruently identified abundance of CEACAM1(+)matrix metalloproteinase-9(+) neutrophils in the ischemi

260 ANK, TRAP, cathepsin K, calcitonin receptor, matrix metalloproteinase 9, NFATc1, DC-STAMP, ATP6v0d1,

261 g the expression of the tumorigenic proteins matrix metalloproteinase-9, nm23, urokinase plasminogen

262 doxorubicin, including improved response in matrix metalloproteinase-9 null mice that had increased

263 me and elevated basal expression of VEGF and matrix metalloproteinase-9 (P < 0.05).

264 activity of the BBB-degrading cyclophilin A-matrix metalloproteinase-9 pathway(19) in cerebrospinal

265 4, suppressed the CypA-nuclear factor-kappaB-matrix-metalloproteinase-9 pathway in pericytes through

266 a proinflammatory CypA-nuclear factor-kappaB-matrix-metalloproteinase-9 pathway in pericytes.

267 interleukin-1b, interleukin-6, endothelin-1, matrix metalloproteinase-9, plasminogen activator inhibi

268 cell adhesion molecule 1, type IV collagen, matrix metalloproteinase 9, platelet-derived growth fact

269 outgrowth of early-stage tumors due to their matrix metalloproteinase-9 production, become dispensabl

270 We previously showed that pro-matrix metalloproteinase-9 (proMMP-9) binds to B chronic

271 deficiency leads to decreased activation of matrix metalloproteinase 9, reduced degradation of colla

272 MAPCs significantly decrease MMP-9 (matrix metalloproteinase-9) release from macrophages, ef

273 A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D,

274 haride), concomitant with increased VEGF and matrix metalloproteinase 9 secretion.

275 CEACAM1 controls matrix metalloproteinase-9 secretion by neutrophils in p

276 ine the effect of recombinant osteopontin on matrix metalloproteinase-9, substrates of matrix metallo

277 erleukin-6, tumor necrosis factor-alpha, and matrix metalloproteinase-9, suggesting that KC may have

278 Matrix metalloproteinase 9 testing in DED is a valuable

279 n (cyclooxygenase-2) and matrix degradation (matrix metalloproteinase-9) that are known to be regulat

280 uld be attributed to changes in TGF-beta and matrix metalloproteinase-9, the downstream effectors of

281 ctor, selectins, inflammatory cytokines, and matrix metalloproteinase-9, the latter incriminated in b

282 itamin C also restricts the up-regulation of matrix-metalloproteinase-9, the major lung protease invo

283 chial artery, matrix metalloproteinase-2 and matrix metalloproteinase-9, tissue metalloproteinase inh

284 cytokine-induced neutrophil chemoattractant, matrix metalloproteinase 9, TNF-alpha, and IL-6.

285 Release of active matrix metalloproteinase 9, TNF-alpha, CXCL8, and IL-10

286 eptor kinase, interleukin-3, interleukin-13, matrix metalloproteinase-9 total, apolipoprotein E and i

287 exhibit a hyperinvasive phenotype (marked by matrix metalloproteinase-9 upregulation, faster invasion

288 educed expression of downstream target genes matrix metalloproteinase 9, urokinase plasminogen activa

289 ion of FR-beta, mannose receptor, IL-10, and matrix metalloproteinase-9 was significantly increased i

290 Myeloperoxidase, D-dimer, and matrix metalloproteinase 9 were not modified.

291 es, the tight junction protein occludin, and matrix metalloproteinase-9 were among the key difference

292 Osteopontin and matrix metalloproteinase-9 were confirmed inside EV.

293 tor, chemokine (C-X-C motif) receptor 4, and matrix metalloproteinase 9, were more highly expressed i

294 ished through the action of gelatinases (eg, matrix metalloproteinase 9), which degrade collagen comp

295 d vascular cellular adhesion molecule-1, and matrix metalloproteinase 9), which represent surrogate i

296 racterized by endocytic markers, but also of matrix metalloproteinase 9, which is not associated with

297 ne array data revealed reduced expression of matrix metalloproteinase 9 with the ablation of either P

298 ell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molec

299 on matrix metalloproteinase-9, substrates of matrix metalloproteinase-9 (zona occludens-1, laminin),

300 acrophages has long been attributed to their matrix metalloproteinase-9 zymogen (proMMP-9).